EMA Upgrades Database to Strengthen Supply Chain Security - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Upgrades Database to Strengthen Supply Chain Security



EMA announced that it has upgraded its EudraGMP database to include information on GDP in addition to GMP. The new EudraGMDP database is a key deliverable of the Falsified Medicines Directive (FMD) that came into effect in January 2013. The aim is to increase supply chain security in the EU by making supervision of manufacturing and distribution of medicines more robust to ensure supplier compliance. Those involved in the supply chain will be able to check information available on their suppliers.

EudraGMDP is a modification of the EudraGMP database, which was first launched in April 2007 to facilitate the exchange of information on compliance and noncompliance with GMP among the regulatory authorities within the European medicines network. The database currently contains manufacturing and import authorisations; GMP certificates; statement of noncompliance with GMP; and GMP inspection plans in countries outside the EU.

Over the next few months, medicines regulatory authorities in EU member states will upload distribution-related information as it becomes available. The additional information will include wholesale distribution authorisations; GDP certificates; statements of noncompliance with GDP; and registrations of manufacturers, importers (including information on their suppliers) and distributors of active substances.

The new system follows the new GMP inspection planning module introduced in December 2012 for countries outside the EU. It was developed to make better use of inspection resources by sharing of information among EU regulators and avoiding redundant inspections.

Most information in EudraGMDP is accessible by the public except for information of commercially or personally confidential nature. The decision on which information can be made public is made by the medicines regulatory authority in the member state that uploads the information to the database.

About the FMD: The directive was adopted to protect patients and consumers from falsified medicines by strengthening supervision of the supply chain of medicinal products and active substances entering the EU. New requirements of the FMD can be divided into four categories: safety features on medicines; supply chain and GDP; active substances and excipients; and Internet sales.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here